IP Group - Remaining on track despite tough markets
IP Group’s private portfolio valuations remained broadly stable in H123, with its c 4.1% NAV decline in total return (TR) terms mostly due to a de rating of listed holdings (Oxford Nanopore, ONT, in particular) and FX headwinds, though subsequently largely offset by a rebound in quoted holdings to date. IP Group’s holding-level liquidity remains firm and 84% of its direct portfolio holdings have a cash runway of 12 months or more. IP Group shares continue to trade at a wide 53% discount to NAV.IP Group is focused on identifying intellectual property (IP), nurturing and building businesses around such IP and then providing capital and support along the journey from cradle to maturity. As of Dec 31 2016, Co.'s portfolio comprised holdings in 90 companies across the four sectors in which Co. operated: IP Healthcare; IP Tech; IP Cleantech; and IP Biotech. Co. is organized into three operating segments: the commercialization of IP via the formation of long-term partner relationships with universities; the management of venture funds focusing on early-stage U.K. technology companies; and the in-licensing of druggable intellectual property from research institutions.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.